Therefore, to elucidate the molecular mechanisms of DLX6-AS1 in regulating bladder cancer progression, we focused on the Wnt/β-catenin signaling pathway, and determined the expression of several key factors including β-catenin, GSK-3β c-myc and cyclin D1. This evidence concerns the gene MYC and urinary bladder carcinoma.